Welcome to LookChem.com Sign In|Join Free

CAS

  • or

16176-68-4

Post Buying Request

16176-68-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

16176-68-4 Usage

Uses

Palmatrubine is a novel inhibitor, a tetrahydroprotoberberine acting as an inhibitor of tissue factor procoagulant.

Check Digit Verification of cas no

The CAS Registry Mumber 16176-68-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,1,7 and 6 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 16176-68:
(7*1)+(6*6)+(5*1)+(4*7)+(3*6)+(2*6)+(1*8)=114
114 % 10 = 4
So 16176-68-4 is a valid CAS Registry Number.

16176-68-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name palmatrubine

1.2 Other means of identification

Product number -
Other names 7,8,13,13A-TETRADEHYDRO-9-HYDROXY-2,3,10-TRIMETHOXYBERBINIUM (REFERENCE GRADE)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16176-68-4 SDS

16176-68-4Downstream Products

16176-68-4Relevant articles and documents

Structure-activity relationships of quaternary protoberberine alkaloids having an antimalarial activity

Iwasa, Kinuko,Nishiyama, Yumi,Ichimaru, Momoyo,Moriyasu, Masataka,Kim, Hye-Sook,Wataya, Yusuke,Yamori, Takao,Takashi, Turuo,Lee, Dong-Ung

, p. 1077 - 1083 (1999)

Seventeen quaternary protoberberine alkaloids related to berberine 1 were tested for antimalarial activity in vitro against Plasmodium falciparum and structure-activity relationships are proposed. The activity of the protoberberine alkaloids was influenced by the type of the oxygen substituents on rings A, C and D and the position of the oxygen functions on ring D. The position of the oxygen functions on ring D and the type of the oxygen substituents at the C-13 position (ring C) strongly influenced the activity. Shifting the oxygen functions at C-9 and C-10 to C-10 and C-11 on ring D resulted in a significant increase in the activity. Compounds bearing a methylenedioxy function at C-2 and C-3 (ring A) or C-9 and C-10 (ring D) showed higher activity than those which have methoxy groups at the same positions. Introduction of a methoxy group into the C-1 position (ring A) decreased the activity. Replacement of a hydroxy group at C-2 or C-3 (ring A) by a methoxy group led to a reduction in the activity. Displacement of a hydroxy function at C-13 (ring C) by the oxygen substituents such as OMe, OEt, OCOOEt, and OCON(Me)2 reduced the activity. In the same replacement at C-9 (ring D), the activity depended upon the type of the oxygen function. Six protoberberines displayed more potent activity than berberine 1. The activity decreased in the order: 10, 11, 17 and 18 > 7 and 8 > 1.

Four proto compound in the preparation of anti-depression drug application

-

Paragraph 0063-0065, (2017/08/25)

The invention discloses application of tetrahydroproberberine compounds to prepare antidepressants. Experiments confirm that tetrahydroproberberine compounds are capable of effectively shortening the swimming motionless time of a depression-model mouse, obviously shortening the tail suspending accumulative motionless time of a depression-model mouse and obviously improving the depression state caused by reserpine of a mouse, and show certain anti-depression effect.

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

-

Page/Page column 70, (2011/02/15)

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16176-68-4